Treating to Reduce Albuminuria and Normalize Hemodynamic Function in Focal ScLerosis With dApagliflozin Trial Effects
Status:
Completed
Trial end date:
2017-04-24
Target enrollment:
Participant gender:
Summary
Patients with Focal Segmental Glomerulosclerosis (FSGS) constitute an increasing proportion
of the total glomerulonephritis (GN) patient cohort in North America while FSGS is a risk
factor for end stage renal failure. Current non-immunological FSGS therapies include the use
of angiotensin converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARB),
to reduce intraglomerular hypertension. Unfortunately, these agents lead to incomplete renal
protection. The aim of the current study is to determine whether the addition of novel sodium
glucose cotransport-2 inhibitors (SGLT2i) to standard of care leads to reduced
intraglomerular pressure and suppression of proteinuria. We hypothesize that combination
therapy of SGLT2i drugs and conventional RAASi results in additive renal protective effects
in FSGS patients. A further goal is to examine mechanisms of SGLT2 inhibition by measuring
renal hemodynamic function and sodium handling. Kidney function will be assessed in FSGS
patients before and after an 8 week treatment with SGLT2i dapagliflozin.
Phase:
Phase 4
Details
Lead Sponsor:
University Health Network, Toronto
Collaborators:
AstraZeneca Toronto General Hospital University of Toronto